The acylating enzyme, ghrelin-O-acyltransferase (GOAT), was recently proposed as a therapeutic target for obesity and type 2 diabetes [76] based on the assumption that it would reduce the production of active ghrelin and thereby decrease meal frequency. Here, GHRL is linked to obesity due to melanocortin 4 receptor deficiency.